Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2013 Mar 1

PMID 23447563

Citations 10

Authors

Chunmei Wang

Luciana P Schwab

Meiyun Fan

Tiffany N Seagroves

John K Buolamwini

Affiliations

Soon will be listed here.

Abstract

Dipyridamole (DPM) is widely used to prevent strokes and vascular thrombosis. Combination therapy of DPM and antimetabolites has shown synergistic anticancer activity. This study investigated the chemopreventive effects of DPM in the mouse mammary tumor virus promoter-driven polyoma middle T oncoprotein metastatic breast cancer model. We also investigated the effects of DPM on gene and miRNA expression. Chemopreventive activity was assessed by comparing the time to onset of palpable lesions, primary tumor growth kinetics, and the number of lung metastases in transgenic mice treated with DPM or vehicle. Gene expression and miRNA expression profiles of mammary tumor tissues were then analyzed using the Affymetrix GeneChip or miRNA 2.0 arrays. Real-time quantitative PCR was used to confirm changes in gene expression. Treatment with DPM beginning at the age of 4 weeks delayed the onset of palpable lesions, delayed tumor progression, and suppressed lung metastasis. Microarray gene expression analysis identified 253 genes differentially expressed between DPM-treated and control mammary tumors. miRNA expression analysis revealed that 53 miRNAs were altered by DPM treatment. The results indicate that DPM has chemoprevention activity against breast cancer tumorigenesis and metastasis in mice. The array analyses provide insights into potential mechanisms of DPM's chemopreventive effects, involving upregulation of several genes and miRNAs known to suppress cancer growth and/or metastasis and downregulation of genes known to promote cancer. Some of these genes have not been previously studied in breast cancer and may serve as novel molecular targets for breast cancer chemoprevention.

Citing Articles

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.

Keller M, Rohlf K, Glotzbach A, Leonhardt G, Luke S, Derksen K J Exp Clin Cancer Res. 2023; 42(1):25.

PMID: 36670508 PMC: 9854078. DOI: 10.1186/s13046-022-02578-w.

The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Epstein P, Basole C, Brocke S Front Cell Dev Biol. 2021; 9:636778.

PMID: 33937235 PMC: 8085600. DOI: 10.3389/fcell.2021.636778.

Enhancing Extracellular Adenosine Levels Restores Barrier Function in Acute Lung Injury Through Expression of Focal Adhesion Proteins.

Wang W, Chen N, Ren D, Davies J, Philip K, Eltzschig H Front Mol Biosci. 2021; 8:636678.

PMID: 33778007 PMC: 7987656. DOI: 10.3389/fmolb.2021.636678.

Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer.

Wang N, Yang B, Zhang X, Wang S, Zheng Y, Li X Front Pharmacol. 2018; 9:1106.

PMID: 30333750 PMC: 6176282. DOI: 10.3389/fphar.2018.01106.

Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.

Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S J Exp Clin Cancer Res. 2017; 36(1):172.

PMID: 29197410 PMC: 5712102. DOI: 10.1186/s13046-017-0635-9.

References

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

WILLSON J, FISCHER P, Tutsch K, Alberti D, Simon K, HAMILTON R . Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res. 1988; 48(19):5585-90. View

Espey D, Wu X, Swan J, Wiggins C, Jim M, Ward E . Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110(10):2119-52. DOI: 10.1002/cncr.23044. View

DeCensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V . Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005; 111(5):650-6. DOI: 10.1161/01.CIR.0000154545.84124.AC. View

Yamamoto Y, Yoshioka Y, Minoura K, Takahashi R, Takeshita F, Taya T . An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011; 10:135. PMC: 3247093. DOI: 10.1186/1476-4598-10-135. View

Crowell J . The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview. Eur J Cancer. 2005; 41(13):1889-910. DOI: 10.1016/j.ejca.2005.04.016. View

Rebbeck T, DeMichele A, Tran T, Panossian S, Bunin G, Troxel A . Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis. 2008; 30(2):269-74. PMC: 2722148. DOI: 10.1093/carcin/bgn247. View

Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz A, Wang Z . A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009; 137(6):1032-46. PMC: 2766609. DOI: 10.1016/j.cell.2009.03.047. View

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66. DOI: 10.3322/canjclin.57.1.43. View

10.

Ellinger-Ziegelbauer H, Kelly K, Siebenlist U . Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of mitogen-activated protein kinase kinase kinase 3. Mol Cell Biol. 1999; 19(5):3857-68. PMC: 84242. DOI: 10.1128/MCB.19.5.3857. View

11.

Saravanan K, Barlow H, Barton M, Calvert A, Golding B, Newell D . Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein. J Med Chem. 2011; 54(6):1847-59. DOI: 10.1021/jm101493z. View

12.

Zetter B . Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993; 4(4):219-29. View

13.

Liu X, Wazer D, Watanabe K, Band V . Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996; 56(14):3371-9. View

14.

Spano D, Marshall J, Marino N, De Martino D, Romano A, Scoppettuolo M . Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis. 2012; 30(1):47-68. PMC: 7654221. DOI: 10.1007/s10585-012-9506-0. View

15.

Foltz C . Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999; 49(3):319-23. View

16.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

17.

Goyal J, Smith K, Cowan J, Wazer D, Lee S, Band V . The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 1998; 58(21):4782-6. View

18.

Wells W, Schwartz G, Morganelli P, Cole B, Gibson J, Kinlaw W . Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat. 2006; 98(2):231-40. DOI: 10.1007/s10549-005-9154-z. View

19.

Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson E . Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010; 28(4):341-7. PMC: 2852471. DOI: 10.1038/nbt.1618. View

20.

White N, Chow T, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H . Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer. 2010; 102(8):1244-53. PMC: 2856011. DOI: 10.1038/sj.bjc.6605634. View